Agios Pharmaceuticals announced it will host a conference call and live webcast on February 12, 2026, at 8:00 a.m. ET to report its fourth quarter and full year 2025 financial results and business highlights. The company also outlined its 2026 strategic priorities and key milestones to accelerate rare disease portfolio growth.

Agios Pharmaceuticals shares surged over 18% following FDA approval of AQVESME (mitapivat) for treating alpha- and beta-thalassemia. The company priced the drug at $425,000 annually in the U.S. and projects $1 billion in global peak-year sales across thalassemia and pyruvate kinase deficiency indications. Management's positive conference call and expansion plans drove investor enthusiasm.

The FDA has approved Agios Pharmaceuticals' AQVESME (mitapivat), an oral pyruvate kinase activator, for treating anemia in adults with alpha- or beta-thalassemia. AQVESME is the only FDA-approved medicine for both non-transfusion-dependent and transfusion-dependent forms of the disease. The approval is based on Phase 3 ENERGIZE and ENERGIZE-T trials showing significant improvements in hemoglobin levels, fatigue, and transfusion burden. The drug will be available in late January 2026 under a REMS program due to hepatocellular injury risks observed in clinical trials.

The sickle cell disease market is projected to grow at a 22.1% CAGR by 2034, driven by increasing disease prevalence, awareness, and advancements in gene therapies, with emerging treatments from multiple pharmaceutical companies.

Agios Pharmaceuticals' stock dropped nearly 50% after mixed Phase 3 trial results for its sickle cell disease drug mitapavit. The drug met one primary endpoint of hemoglobin response but failed to significantly reduce sickle cell pain crises.

Agios Pharmaceuticals received a positive opinion from the European Medicines Agency for PYRUKYND, a treatment for thalassemia in adults. The drug shows promise in treating anemia associated with alpha- and beta-thalassemia, with a final European Commission decision expected in early 2026.

Agios Pharmaceuticals will host a Q3 2025 financial results conference call on October 30, and announced an FDA PDUFA goal date extension for PYRUKYND in thalassemia treatment. The company also received approval for PYRUKYND in Saudi Arabia.

The thalassemia treatment market is expected to grow significantly by 2034, driven by novel drug developments, emerging therapies like pyruvate kinase activators, and improved diagnostic technologies. Currently, no approved drugs exist for alpha thalassemia, but several treatments are available for beta thalassemia.

Atavistik Bio appointed Susan Pandya, M.D., as Chief Medical Officer, bringing 20 years of drug development expertise in precision medicine. She will lead clinical development strategy, focusing on the Phase 1 clinical trial of ATV-1601, an allosteric selective inhibitor for AKT1 E17K-driven solid tumors.

Agios Pharmaceuticals will host a conference call on July 31, 2025 at 8:00am ET to report its second quarter 2025 financial results and discuss business highlights, with a live webcast available on their website.

Law firm Kaskela Law LLC is investigating Trevi Therapeutics for potential securities law violations or breaches of fiduciary duties, encouraging long-term investors to contact them for more information.

Agios Pharmaceuticals, a leader in cellular metabolism and pyruvate kinase (PK) activation, announced that it will be presenting at the Goldman Sachs 46th Annual Global Healthcare Conference and the 2025 RBC Capital Markets Global Healthcare Conference. The company will highlight its PK activation portfolio and new data in rare blood disorders.